Navigation Links
Embryonic Stem Cell Protein Inhibits Melanoma
Date:3/3/2008

Finding helps identify cellular pathways involved in cancer metastasis

MONDAY, March 3 (HealthDay News) -- A protein called Lefty that regulates development of human embryonic stem cells can inhibit the growth and spread of deadly melanomas and aggressive breast cancers, says a study by researchers at Northwestern University in Chicago.

The findings, published in this week's online issue of the Proceedings of the National Academy of Sciences, add to the team's previous efforts to identify the genes and cellular pathways involved in cancer metastasis, and may help lead to new kinds of cancer treatments.

Lefty is secreted only in human embryonic stem cells (hESCs) and not in any other types of stem cells, including those isolated from amniotic fluid, umbilical cord blood or adult bone marrow, the researchers said.

In an earlier study, the Northwestern team found that aggressive melanoma and breast cancer produce a protein called Nodal, which may serve as a marker of aggressive behavior in human cancers.

In this new study, the researchers exposed metastatic melanoma and breast cancer cells to hESCs containing Lefty and noted a dramatic reduction in Nodal production in the cancer cells, along with decreased growth and an increase in programmed cell death (apoptosis).

"The remarkable similarity of the responses of the two tumor types is likely attributable to the commonality of plasticity (for example, the aberrant and unregulated expression of Nodal) that indiscriminately unifies highly aggressive cancer cells, regardless of their tissue of origin," team leader Dr. Mary J. C. Hendrix, scientific director of the Children's Memorial Research Center and professor in The Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Feinberg School of Medicine, said in a prepared statement.

"Further, the tumor suppressive effects of the hESC microenvironment, by neutra
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Protein in embryonic stem cells control malignant tumor cells
2. Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development
3. A functional immune system can be derived from embryonic stem cells, preliminary study finds
4. UCLA stem cell scientists reprogram human skin cells into embryonic stem cells
5. Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells
6. Embryonic Stem Cells Create Healthy Muscle in Mice
7. Human embryonic stem cell lines created that avoid immune rejection
8. UC Davis researchers find evidence of mature heart cell potential in embryonic stem cells
9. Serum carcinoembryonic antigen level can reflect adrenal adenoma
10. Study Probes Difference Between Embryonic, Adult Stem Cells
11. Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Embryonic Stem Cell Protein Inhibits Melanoma
Embryonic Stem Cell Protein Inhibits Melanoma
Other Medicine News:Health News:Penn talks at ASCB touch on cancer, neurodegenerative diseases, and MD 2Health News:Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health 2Health News:Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health 3Health News:Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health 4Health News:New Study Links Animal Agriculture to More Than 20% of MRSA Infections in the Netherlands 2Health News:Neuro Kinetics Appoints Dr. Terri Ives Clinical Director, Audiology 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 3Health News:Aerosol launches immune response in lungs to wipe out lethal infections 2Health News:Aerosol launches immune response in lungs to wipe out lethal infections 3
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Emission capture study funded for paper industry 10353 1Emission capture study funded for paper industry 10353 2Emission capture study funded for paper industry 10353 3Fear of being laughed at crosses cultural boundaries 10348 1Fear of being laughed at crosses cultural boundaries 10348 2Fear of being laughed at crosses cultural boundaries 10348 3Fear of being laughed at crosses cultural boundaries 10348 4Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 1Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 2